Press Releases

Lexicon Pharmaceuticals Announces Publication of Positive Data for Zynquista™ (sotagliflozin) on Cardiorenal Clinical Biomarkers in Adults with Type 1 Diabetes	Aug 08, 2019
Lexicon Pharmaceuticals Reports Second Quarter 2019 Financial Results and Provides a Business Update	Jul 31, 2019
Lexicon Pharmaceuticals Announces Date Change for Second Quarter 2019 Financial Results Conference Call and Webcast to July 31, 2019	Jul 30, 2019
Lexicon Pharmaceuticals Provides Preliminary Update for Zynquista™ (sotagliflozin) Type 2 Diabetes Phase 3 Program	Jul 26, 2019
Lexicon Pharmaceuticals to Host Second Quarter 2019 Financial Results Conference Call and Webcast on August 1, 2019	Jul 25, 2019
Lexicon Pharmaceuticals to Present New Clinical Data at 79th American Diabetes Association Scientific Sessions	Jun 04, 2019
Lexicon Pharmaceuticals to Present at Upcoming Investor Conference	May 23, 2019
Lexicon Pharmaceuticals to Present at Upcoming Investor Conference	May 08, 2019
Lexicon Pharmaceuticals Reports First Quarter 2019 Financial Results and Provides a Business Update	May 01, 2019
Zynquista™ Now Approved in the European Union for Treatment of Adults with Type 1 Diabetes	Apr 26, 2019